TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Other Receivables
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Other Receivables of $207.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2026-06-30 was $396.00K, a 121.23% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2026-03-31 was -$189.00K, a 144.06% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2025-12-31 was $336.00K, a 118.18% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2025-09-30 was -$190.00K.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for fiscal 2025 was $754.00K, a 266.02% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for fiscal 2024 was $206.00K.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for fiscal 2023 was -$2.49M, a 171.35% decline from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other receivables for fiscal 2022 was $3.49M, a 4680.82% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2026-06-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $207.00K 10-Q · filed 2026-08-06 | $543.00K derived: sum of 3 quarters · filed 2026-08-06 | $353.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$189.00K 10-Q · filed 2026-05-06 | $147.00K derived: sum of 2 quarters · filed 2026-05-06 | -$43.00K derived: sum of 3 quarters · filed 2026-05-06 | $136.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $336.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $146.00K derived: sum of 2 quarters · filed 2026-02-23 | $325.00K derived: sum of 3 quarters · filed 2026-08-06 | $754.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | -$190.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$11.00K derived: sum of 2 quarters · filed 2026-08-06 | $418.00K 10-Q · filed 2025-11-04 | $572.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $179.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $608.00K 10-Q · filed 2026-08-06 | $762.00K derived: sum of 3 quarters · filed 2026-08-06 | $596.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $429.00K 10-Q · filed 2026-05-06 | $583.00K derived: sum of 2 quarters · filed 2026-05-06 | $417.00K derived: sum of 3 quarters · filed 2026-05-06 | $252.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$12.00K derived: sum of 2 quarters · filed 2026-02-23 | -$177.00K derived: sum of 3 quarters · filed 2026-02-23 | $206.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | -$166.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$331.00K derived: sum of 2 quarters · filed 2025-11-04 | $52.00K 10-Q · filed 2025-11-04 | $136.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $218.00K 10-Q · filed 2025-08-06 | $302.00K derived: sum of 3 quarters · filed 2026-02-23 | $1.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $383.00K 10-Q · filed 2025-05-01 | $467.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.23M derived: sum of 3 quarters · filed 2026-02-23 | $1.06M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $846.00K derived: sum of 2 quarters · filed 2026-02-23 | $675.00K derived: sum of 3 quarters · filed 2026-02-23 | -$2.49M 10-K · filed 2026-02-23 |
| 2023-09-30 | $762.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $591.00K derived: sum of 2 quarters · filed 2024-11-13 | -$2.57M 10-Q · filed 2024-11-13 | -$2.99M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.34M 10-Q · filed 2024-08-08 | -$3.75M derived: sum of 3 quarters · filed 2025-02-25 | -$356.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$3.17M 10-Q · filed 2024-05-08 | -$3.58M derived: sum of 2 quarters · filed 2025-02-25 | -$185.00K derived: sum of 3 quarters · filed 2025-02-25 | $100.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $2.98M derived: sum of 2 quarters · filed 2025-02-25 | $3.27M derived: sum of 3 quarters · filed 2025-02-25 | $3.49M 10-K · filed 2025-02-25 |
| 2022-09-30 | $3.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.68M derived: sum of 2 quarters · filed 2023-11-09 | $3.90M 10-Q · filed 2023-11-09 | $3.86M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $285.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $510.00K 10-Q · filed 2023-08-10 | $464.00K derived: sum of 3 quarters · filed 2023-08-10 | $446.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $225.00K 10-Q · filed 2023-05-09 | $179.00K derived: sum of 2 quarters · filed 2023-05-09 | $161.00K derived: sum of 3 quarters · filed 2023-05-09 | $71.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$64.00K derived: sum of 2 quarters · filed 2023-03-17 | -$154.00K derived: sum of 3 quarters · filed 2023-03-17 | $73.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | -$18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$108.00K derived: sum of 2 quarters · filed 2022-11-09 | $119.00K 10-Q · filed 2022-11-09 | $137.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $137.00K 10-Q · filed 2022-08-11 | $155.00K derived: sum of 3 quarters · filed 2022-08-11 | $155.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $227.00K 10-Q · filed 2022-05-11 | $245.00K derived: sum of 2 quarters · filed 2022-05-11 | $245.00K derived: sum of 3 quarters · filed 2022-05-11 | $215.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $18.00K derived: sum of 2 quarters · filed 2022-03-14 | -$12.00K derived: sum of 3 quarters · filed 2022-03-14 | -$16.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$30.00K derived: sum of 2 quarters · filed 2021-11-10 | -$34.00K 10-Q · filed 2021-11-10 | $2.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$34.00K 10-Q · filed 2021-08-05 | $2.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$4.00K 10-Q · filed 2021-05-11 | $32.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $32.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | -$4.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |